Our future research will focus on the following key directions: (1) Lentiviral modulation of PAK6 in SCLC models to define its roles in proliferation, invasion, and chemoresistance; (2) Preclinical evaluation of PAK6 inhibitors in patient-derived xenografts; (3) Multi-center trials assessing PAK6’s utility in chemoresistance prediction and subtype stratification (e.g., cisplatin-resistant vs. sensitive SCLC). This evidence concerns the gene PAK6 and small cell lung carcinoma.